JP2024502175A - Nuakキナーゼの阻害剤としてのイソインドリノンアミノピリミジン化合物、その組成物及び使用 - Google Patents

Nuakキナーゼの阻害剤としてのイソインドリノンアミノピリミジン化合物、その組成物及び使用 Download PDF

Info

Publication number
JP2024502175A
JP2024502175A JP2023541658A JP2023541658A JP2024502175A JP 2024502175 A JP2024502175 A JP 2024502175A JP 2023541658 A JP2023541658 A JP 2023541658A JP 2023541658 A JP2023541658 A JP 2023541658A JP 2024502175 A JP2024502175 A JP 2024502175A
Authority
JP
Japan
Prior art keywords
alkyl
alkylene
heterocycloalkyl
haloalkyl
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023541658A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024502175A5 (cg-RX-API-DMAC7.html
Inventor
アル-アワル、リマ
アッティサーノ、リリアーナ
イサーク、メトヴィン
リウ、ヨン
スマイル、デイヴィッド
ユーリン、デイヴィッド
ウラナ、ジェフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Toronto
Original Assignee
University of Toronto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Toronto filed Critical University of Toronto
Publication of JP2024502175A publication Critical patent/JP2024502175A/ja
Publication of JP2024502175A5 publication Critical patent/JP2024502175A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023541658A 2021-01-07 2022-01-07 Nuakキナーゼの阻害剤としてのイソインドリノンアミノピリミジン化合物、その組成物及び使用 Pending JP2024502175A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163134747P 2021-01-07 2021-01-07
US63/134,747 2021-01-07
PCT/CA2022/050016 WO2022147622A1 (en) 2021-01-07 2022-01-07 Isoindolinone aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof

Publications (2)

Publication Number Publication Date
JP2024502175A true JP2024502175A (ja) 2024-01-17
JP2024502175A5 JP2024502175A5 (cg-RX-API-DMAC7.html) 2024-12-10

Family

ID=82357069

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023541658A Pending JP2024502175A (ja) 2021-01-07 2022-01-07 Nuakキナーゼの阻害剤としてのイソインドリノンアミノピリミジン化合物、その組成物及び使用

Country Status (7)

Country Link
US (1) US12643886B2 (cg-RX-API-DMAC7.html)
EP (1) EP4277902A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024502175A (cg-RX-API-DMAC7.html)
CN (1) CN116940565A (cg-RX-API-DMAC7.html)
AU (1) AU2022206470A1 (cg-RX-API-DMAC7.html)
CA (1) CA3204401A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022147622A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102939283B1 (ko) * 2022-05-03 2026-03-13 한국화학연구원 5-클로로-2,4-다이아미노피리미딘을 포함하는 키나아제 억제 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
EP4587423A1 (en) * 2022-09-12 2025-07-23 MiHKAL GmbH Novel nootropic prodrugs of phenethylamine
KR20240156074A (ko) * 2023-04-21 2024-10-29 (주)엠디바이오팜 Hpk1 및 mlk3 저해제 및 이를 함유하는 항암용 조성물
CN116947764B9 (zh) * 2023-07-13 2025-07-25 特科罗生物科技(成都)有限公司 一种嘧啶胺类nuak抑制剂及其制备方法和用途
KR20250041906A (ko) * 2023-09-19 2025-03-26 (주)엠디바이오팜 Hpk1 및 mlk3 저해 활성을 갖는 신규한 화합물 및 이를 함유하는 항암용 조성물

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007502260A (ja) * 2003-08-15 2007-02-08 ノバルティス アクチエンゲゼルシャフト 新生物疾患、炎症および免疫障害の処置に有用な2,4−ピリミジンジアミン
JP2008510691A (ja) * 2004-08-20 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Plkインヒビターとしてのピリミジン化合物
JP2008510763A (ja) * 2004-08-27 2008-04-10 ノバルティス アクチエンゲゼルシャフト ピリミジン誘導体
JP2009520807A (ja) * 2005-12-21 2009-05-28 ファイザー・プロダクツ・インク 異常細胞増殖を治療するためのピリミジン誘導体
JP2010507665A (ja) * 2006-10-23 2010-03-11 セファロン、インク. ALK阻害剤およびc−MET阻害剤としての2,4−ジアミノピリミジンの縮合二環式誘導体
JP2011523646A (ja) * 2008-05-21 2011-08-18 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのリン誘導体
JP2013539795A (ja) * 2010-10-14 2013-10-28 アリアド・ファーマシューティカルズ・インコーポレイテッド Egfr発動性がんの細胞増殖の阻害方法
JP2019531315A (ja) * 2017-01-26 2019-10-31 ハンミ ファーマシューティカルズ カンパニー リミテッド ピリミジン化合物及びその医薬用途
JP2023527242A (ja) * 2020-05-29 2023-06-27 南京正大天晴制薬有限公司 Axl阻害剤であるピリミジン系化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20170317T1 (hr) 2008-02-15 2017-04-21 Rigel Pharmaceuticals, Inc. Spojevi pirimidin-2-amina i njihova uporaba kao inhibitora jak kinaza
WO2010090875A1 (en) * 2009-01-21 2010-08-12 Rigel Pharmaceuticals, Inc. Derivatives of n2-(3-pyridil or phenyl)-n4-(4-piperidyl)-2,4-pyrimidinediamine useful in the treatment of inflammatory, autoimmune or proliferative diseases
CA2788450A1 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted naphthalenyl-pyrimidine compounds
US20230096028A1 (en) 2019-03-01 2023-03-30 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
HUE065486T2 (hu) 2019-05-10 2024-05-28 Deciphera Pharmaceuticals Llc Fenilaminopirimidinamid autophágia inhibitorok és azok felhasználási eljárásai

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007502260A (ja) * 2003-08-15 2007-02-08 ノバルティス アクチエンゲゼルシャフト 新生物疾患、炎症および免疫障害の処置に有用な2,4−ピリミジンジアミン
JP2008510691A (ja) * 2004-08-20 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Plkインヒビターとしてのピリミジン化合物
JP2008510763A (ja) * 2004-08-27 2008-04-10 ノバルティス アクチエンゲゼルシャフト ピリミジン誘導体
JP2009520807A (ja) * 2005-12-21 2009-05-28 ファイザー・プロダクツ・インク 異常細胞増殖を治療するためのピリミジン誘導体
JP2010507665A (ja) * 2006-10-23 2010-03-11 セファロン、インク. ALK阻害剤およびc−MET阻害剤としての2,4−ジアミノピリミジンの縮合二環式誘導体
JP2011523646A (ja) * 2008-05-21 2011-08-18 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのリン誘導体
JP2013539795A (ja) * 2010-10-14 2013-10-28 アリアド・ファーマシューティカルズ・インコーポレイテッド Egfr発動性がんの細胞増殖の阻害方法
JP2019531315A (ja) * 2017-01-26 2019-10-31 ハンミ ファーマシューティカルズ カンパニー リミテッド ピリミジン化合物及びその医薬用途
JP2023527242A (ja) * 2020-05-29 2023-06-27 南京正大天晴制薬有限公司 Axl阻害剤であるピリミジン系化合物

Also Published As

Publication number Publication date
EP4277902A4 (en) 2024-12-18
EP4277902A1 (en) 2023-11-22
AU2022206470A9 (en) 2024-09-26
US12643886B2 (en) 2026-06-02
AU2022206470A1 (en) 2023-07-27
US20240092763A1 (en) 2024-03-21
CA3204401A1 (en) 2022-07-14
CN116940565A (zh) 2023-10-24
WO2022147622A1 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
ES2443127T3 (es) Nuevos derivados tricíclicos o sales de éstos farmacéuticamente aceptables, su procedimiento de fabricación y composiciones farmacéuticas que los contienen
CN116940565A (zh) 作为nuak激酶的抑制剂的异吲哚啉酮氨基嘧啶化合物、其组合物和用途
EP3728232B1 (en) Novel quinolone compounds as inhibitors of the bcl6 btb domain protein-protein interaction and/or as bcl6 degraders
JP2024502174A (ja) Nuakキナーゼの阻害剤としてのチエニル及びシクロアルキルアミノピリミジン化合物、その組成物及び使用
JP2019517464A (ja) 血漿カリクレインインヒビターとしてのピラゾール誘導体
CA3073977A1 (en) Inhibitors of wdr5 protein-protein binding
JP2019509304A (ja) インテグリンアンタゴニストとしてのナフチリジン
JP6268276B2 (ja) PERK阻害剤としての新規なN(2,3−ジヒドロ−1H−ピロロ[2,3−b]ピリジン−5−イル)−4−キナゾリンアミン誘導体およびN−(2,3−ジヒドロ−1H−インドール−5−イル)−4−キナゾリンアミン誘導体
JPWO2004108724A1 (ja) 3環系化合物
FR3008978A1 (fr) "nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
CA3086368A1 (en) Novel deuterated compounds as inhibitors of the bcl6 btb domain protein-protein interaction and/or as bcl6 degraders
KR20190026905A (ko) 모노시클릭 헤테로아릴 치환된 화합물
CN107787321A (zh) 新型5‑ht2拮抗剂
CN109734677A (zh) 抑制组蛋白赖氨酸甲基转移酶nsd2的小分子化合物及其应用
CN114502161B (zh) 具有心肌细胞增殖活性的杂环衍生物在治疗心脏病中的用途
CA3086362C (en) Quinolone compounds as inhibitors of the bcl6 btb domain protein-protein interaction and/or as bcl6 degraders
HK40088982A (en) Lpa receptor antagonists and uses thereof
HK40088982B (en) Lpa receptor antagonists and uses thereof
EP4654966A1 (en) Methods and compositions for treatment of obesity and diseases associated with fat cell enlargement
CN120865158A (zh) 含吡唑结构的吲哚啉类化合物及其制备方法和应用
CN111187262A (zh) 咪唑并[1,2-a]吡啶衍生物及其制备方法和应用
HK40049146A (en) Fused bicyclic compounds for the treatment of disease
FR2934858A1 (fr) Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250909

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250910

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260303